Stay updated on Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.

Latest updates to the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page
- CheckyesterdayChange DetectedA new revision entry (v3.5.4) was added to the study record history, representing an updated submission to the record. The previous revision (v3.5.3) was removed from the visible history.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s UI/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3.” This reflects a change in the site’s revision/version rather than a modification to the underlying clinical trial record.SummaryDifference0.1%

- Check29 days agoChange DetectedAdded revision: v3.5.2; removed revision: v3.5.0.SummaryDifference0.1%

- Check36 days agoChange DetectedAdded new sections for Contacts/Locations and Study Status in the record history to reflect updated metadata for the trial.SummaryDifference0.4%

- Check58 days agoChange DetectedRevision v3.5.0 was added to the history and Revision v3.4.3 was removed.SummaryDifference0.1%

- Check65 days agoChange DetectedA new revision entry (v3.4.3) was added to the history and the previous revision (v3.4.2) was removed.SummaryDifference0.1%

Stay in the know with updates to Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.